FDA Approves New Treatment For Adults With Relapsed Or Refractory Large-B-Cell Lymphoma PRNewswireBristol Myers Squibb's CAR-T liso-cel wins long-delayed FDA nod FiercePharmaLiso-cel Receives FDA Approval for the Treatment of R/R Large B-Cell Lymphoma Cancer NetworkFDA Approves Liso-Cel for Refractory Large B-Cell Lymphoma OncLiveU.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel), a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma Business WireView Full Coverage on Google News

NEXT
BING NEWS:
  • Liso-Cel Has Favorable Safety Profile for Outpatients With Large B-Cell Lymphoma
    For patients with relapsed/refractory large B-cell lymphoma (LBCL), the autologous, CD19-directed, 4-1BB chimeric antigen receptor T-cell product, lisocabtagene maraleucel (liso-cel), is safe for ...
    10/7/2024 - 8:04 pm | View Link
  • FDA approves Roche's $90,000 lymphoma combination
    The FDA has quickly approved a new antibody treatment for an aggressive ... (BR) for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have received at least two prior ...
    10/1/2024 - 1:00 pm | View Link
  • AbbVie’s novel epkinly results in meaningful treatment response in patients with treatment-refractory lymphoma
    Epkinly showed an overall response rate of 82% with 62.5% of patients achieving complete response. 65% of patients had grade 1-2 cytokine release syndrome (CRS), though severe cases (grade 3) were ...
    10/1/2024 - 1:22 am | View Link
  • More

 

NEXT
Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

Movies With Butter More Movie News

More U.s. News